{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"19.8","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"22.5","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Sustained objective response was defined as a PR (Partial Response: ≥ 50% decrease in the sum of the products of the 2 perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements) or CR (Complete Response: disappearance of all target lesions) lasting at least 8 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nsunitinib malate: Given PO\n\ndiagnostic laboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG000","title":"Stratum A: Recurrent High Grade Glioma"},{"description":"Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nsunitinib malate: Given PO\n\ndiagnostic laboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG001","title":"Stratum B: Recurrent Ependymoma"}],"paramType":"NUMBER","populationDescription":"One patient in Stratum A was excluded because the patient did not receive study drug and therefore was not evaluable for response.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Sustained Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}